Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG)
Location: United States
Employees: 51-200
Total raised: $281M
Investors 2
| Date | Name | Website |
| - | NFLS - Piv... | pivotalbio... |
| - | TPG | tpg.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 26.03.2020 | Series D | $110M | - |
| 07.06.2018 | Series C | $85M | TPG |
| 21.03.2017 | Series B | $64M | - |
| 23.07.2015 | Series A | $22M | - |
Mentions in press and media 17
| Date | Title | Description |
| 26.03.2020 | SutroVax lands another $100M+ in upstart quest against Pfizer’s blockbuster Prevnar 13 | For the last half-decade, in a facility just south of South San Francisco, the spinoff of a small Stanford spinout has been quietly gunning for Pfizer and the world’s most lucrative vaccine market. Now, they say they’re read... |
| 26.03.2020 | SutroVax Raises $110M in Series D Financing | SutroVax, a Foster City, Calif.-based biopharmaceutical company dedicated to the delivery of novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, closed a $110m Series D financing. Th... |
| 26.03.2020 | SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia | Foster City, CA, March 26, 2020 – SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced ... |
| 26.03.2020 | SutroVax Secures $110M Series D | FOSTER CITY, CA, SutroVax today announced the closing of a $110 million Series D preferred stock financing. >> Click here for more funding data on SutroVax >> To export SutroVax funding data to PDF and Excel, click here S... |
| 08.06.2018 | Term Sheet — Friday, June 8 | M&A OUTLOOK Good morning, Term Sheet readers. Paid Content You can't secure what you can't see From ExtraHop • Cross-border deal activity isn’t slowing down: Growing trade disputes between the United States and countries around the worl... |
| 07.06.2018 | SutroVax Raises $85M in Series C Financing | SutroVax, a Foster City, CA-based independent vaccine platform and development company, closed an $85m Series C financing. The round was led by new investor TPG Growth, with participation from new investors Medicxi and Foresite Capital and ... |
| 07.06.2018 | TPG Leads $85M Series C for SutroVax | SutroVax, a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases, today announced the closing of an upsized $85 million Serie... |
| 07.06.2018 | SutroVax Completes $85M Series C Round | FOSTER CITY, CA, SutroVax, a biopharmaceutical company, has secured $85 million in Series C financing. >> Click here for more funding data on SutroVax >> To export SutroVax funding data to PDF and Excel, click here SutroV... |
| 07.06.2018 | SutroVax picks up $85 million in Series C round for pneumococcal vaccine | The company will use the funding to bring its pneumococcal conjugate vaccine into clinical testing. The company’s website states that it has generated preclinical proof-of-concept for the broad-spectrum vaccine in head-to-head studies again... |
| 22.03.2017 | Term Sheet — Wednesday, March 22 | SCREAMING DOWN While sifting through the news I missed on my vacation, one deal stuck out to me for not getting much media attention: Visible Measures sold to AcuityAds for $10 million. It’s a tiny deal, but it deserves a second look for tw... |
Show more